MBX Biosciences MBX, a clinical-stage biotech focused on developing treatments for endocrine and metabolic disorders, set terms for its initial public offering on Monday, with plans to offer 8.5 ...

MBX Biosciences (MBX) announced the appointments of Chatan Charan, Ph.D. as Senior Vice President, Pharmaceutical Development and Chemistry, Manufacturing and Controls, CMC, and Mark Hope as ...

CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of ...

CARMEL, Ind., June 16, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...

Investing.com -- Three major investment firms started research coverage of MBX Biosciences stock on Tuesday, each assigning a Buy rating to the biotechnology company. Analysts at Jefferies ...

Clinical-stage biopharmaceutical company MBX Biosciences (NASDAQ:MBX) priced its initial public offering of 10.2M shares at $16.00 per share. The gross proceeds are expected to be $163.2M.

On Tuesday, MBX Biosciences Inc. (NASDAQ:MBX) revealed results from its Phase 1 single ascending dose and multiple ascending dose trial of MBX 1416 in healthy adult volunteers. MBX 1416 is the ...

The recent price decline of 17% in MBX Biosciences, Inc.'s stock may have disappointed insiders who bought US$534.5k worth of shares at an average price of US$10.69 in the past 12 months.

MBX Biosciences is advancing a unique prodrug pipeline with key GLP-1 assets and a pivotal Phase 2 readout in hypoparathyroidism. Find out why MBX stock is a buy.

MBX Biosciences’ IPO-backed MBX 2109 shows strong early data. Find out why MBX stock presents an opportunity, but phase 2 results remain a key factor.

MBX Biosciences Inc. company facts, information and financial ratios from MarketWatch.